Abstracts tagged "monocytes and systemic lupus erythematosus (SLE)"

Abstract Number: 2643 • 2017 ACR/ARHP Annual Meeting
HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients
Loreto Cuitino^1,2, Javiera Obreque^1,2, Patricia Gajardo-Meneses^1,2, Gonzalo P. Méndez^2,3, Alexis M. Kalergis^2,4 and Carolina Llanos^1,2, ¹Departamento de Inmunología Clínica y Reumatología, Santiago, Chile, ²Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, ³Departamento de Anatomía Patológica, Santiago, Chile, ⁴Millennium Institute on Immunology and Immunotherapy and Departamento de Endocrinología, Santiago, Chile
Background/Purpose: It is well established that up to 70% of systemic lupus erythematosus (SLE) patients will develop Lupus Nephritis (LN). Recent studies have revealed that…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 210 • 2015 ACR/ARHP Annual Meeting
Phenotypically Divergences of Monocyte Subsets and Microparticles in Systemic Lupus Erythematosus Patients
Catalina Burbano¹, Gloria Vásquez², Mauricio Rojas³ and Diana Castano⁴, ¹Corporación Ciencias Básicas Biomédicas, Grupo de Inmunología celular e Inmunogenética, Universidad de Antioquia. Medellín, Antioquia, Colombia., Medellin, Colombia, ²Rheumatology, Universidad de Antioquia, Medellin, Colombia, ³Unidad de Citometría de Flujo, Universidad de Antioquia. Medellín, Antioquia, Colombia., Medellin, Colombia, ⁴Grupo Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia
Background/Purpose: Mononuclear phagocytes depurate apoptotic cells, microparticles (MPs), and immune complexes (IC), leading to a tolerant or inflammatory microenvironment. The MPs, vesicular structures mainly produced…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 1861 • 2015 ACR/ARHP Annual Meeting
Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis and the Prothrombotic and Proinflammatory Activities of Monocytes
Carlos Perez-Sanchez¹, M.Ángeles Aguirre Zamorano¹, María Galindo², Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Pedro Segui³, Eduardo Collantes-Estevez¹, Mª Jose Cuadrado⁴ and Chary Lopez-Pedrera¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, ⁴Lupus Research Unit, St Thomas Hospital, London, United Kingdom
Background/Purpose: Atherothrombosis in systemic lupus erythematosus (SLE) has been related to the combined effects of autoimmune elements and cells of the immune system, where monocytes…
Abstract Number: 2694 • 2014 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator (BLyS) Promotes Dysregulated Monocyte Function in Systemic Lupus Erythematosus(SLE)
Eoghan M. McCarthy¹, Joan Ní Gabhann², Siobhán Smith², Lorraine O' Neill³, Eamonn S. Molloy⁴, Donough Howard¹, Paul G. O'Connell¹, S. Donnelly⁵, Grainne M. Kearns⁶ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁶Rheumatology Department, Beaumont Hospital, Dublin, Ireland
Background/Purpose SLE involves complex interactions between the innate and adaptive immune systems. Monocytes are increasingly recognised to play a key role in the dysregulated immune…
Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting
Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Zhongbo Jin¹, Mark A. Jensen², Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁶, Kevin G. Moder⁴, Vaidehi Chowdhary³ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Dept of Rheumatology, Mayo Clinc, Rochester, MN
Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE). IFN gene expression signatures have been observed in whole blood and mixed peripheral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].